Imperial Innovations, the technology commercialisation company of Imperial College London, has completed its first investment in a biotech company since its private placement in April 2005. The company has invested into Imperial spin-out, NanoBioDesign, an organisation developing a range of screening systems to speed up the drug discovery process.
GP and Katalist's founders are planning bolt-ons for the food and pharma supply chain software firm
Italian sports technology provider first sale attempt was hampered by the onset of COVID-19 in early 2020
Nick Chronias will lead the firm’s focus on private credit and private infrastructure secondaries
Dörte Höppner joined the GP in 2017 and will be responsible for its ESG initiatives globally